Email Marketing Integration With POS System
August 12, 2019 Business , Internet Geek Girl
As you market your company and brand, your focus should be on fulfilling your customers’ current and future needs, where possible to predict. Your sales approach is impacted by your marketing approach, so cooperation and communication among your team members are crucial. Everyone in your organization should own the marketing campaign.
Marketing is a crucial aspect of an enterprise and needs research, planning, time, and financing to succeed. Here’s how to grow your business by linking your POS system to your email marketing software using several simple tactics. How to Get the Most out of Email Marketing Integration
POS systems are capable of amassing exponential volumes of data. The logical question arises: what do I do with all that data? A large number of small business owners opt to use an email marketing service provider (EMSP) to manage the data collected by their POS. There are three basic components of email marketing software that you need to grasp to get the most out of integrating email marketing at the point of sale – campaigns, lists, and reports.
Here’s how to create and manage these three components. Customizing and Implementing Email Campaigns
Customization and automation features make it easy to send emails, newsletters, and other materials to your customers. To avoid excessiveness, don’t forget to use specifics to drive campaign focus.
Keep track of customer purchase history and buying habits at the POS and redeem and track coupons and discounts offered through email campaigns.
POS systems make using an EMSP easier by saving you time with ready templates. You can create a custom one or use a standard one and make as many as you need. To automate campaign timing and audience, create or use pre-determined workflows. Creating and Managing a List of Subscribers
When using an EMSP, creating subscriber lists has never been easier. All you need to do is sync the customer’s POS interaction and collect the data. Now, your subscriber list is at your fingertips.
At the POS, use the information collected from deliveries and emailed receipts to create new subscribers. To keep track of individual contact preferences, add notes to new and existing contacts. Sync existing contacts from any apps you use and from your Clover Point of Sale . Try EMSPs like MailChimp if you have multiple apps to sync to. Such providers integrate with hundreds of apps.
The next step is to embed a customizable, auto-generated form for signing up wherever you have an existing web presence. Above all, you have the peace of mind knowing that the EMSP takes care of the “unsubscribe” functions for you. Detailed Reporting Features
With the use of reporting features, you can gain insight into the most effective ways to reach customers. Integrate reports across platforms to see which campaigns correlate with higher sales Reports such as, “Sales by Hour” help dictate the content of campaigns and special offers Using the EMSP Subscriber Profiles provide information about the most engaged customers Open and click rates show which content is most viewed and where View the distribution of subscribers across email platforms to optimize formatting Affiliate Marketing
One very popular form of marketing is affiliate marketing, a performance-based approach. It involves a business paying one or more affiliates for each customer or visitor the affiliate has attracted. Affiliate marketing has four components. These are the brand or dealer, the customer, the publisher or exhibitor, and the network itself. In fact, the market has become more complex. At the moment other players, such as third party vendors and super affiliates, are available.
Affiliate marketing is not unlike other internet marketing methods because affiliates often resort to standard advertising techniques. Among these are email marketing, organic search engine optimization (SEO), content marketing, and display advertising.
Services offered by a partner or publication of product reviews are among the less traditional techniques. It is often claimed that affiliates are a company’s extended distribution organization, but there is more to the term ‘affiliate marketing’. Going beyond that, there are some differences between the two, such as the fact that one of these refers to the fact that affiliate marketers have little or no impact on a possibility in the conversion process after the potential customer has reached the advertised website. Advertiser sellers can control and manage the process to the point where the customer buys something or signs a contract. Develop a Link Building Plan
It’s necessary to develop a link building plan with specific tactics to take your products to the top. These include guest contributions and influencer marketing. You should use these tactics to increase your chances of success.
To gain market share, you must first sell your product for a low price. With a low barrier to entry, a lot of people will shop early and leave ratings that you will use in the future to increase your revenue.
Guest posts on websites will get you followers and bring them to your company. In addition you get a part of the authority of your customers for your brand. You can use customer information and purchase history from your POS system to establish customer segments such as loyalty card members, VIPs, or purchasers of specific products. You can then use this information to target your email campaigns to customer needs and preferences. Connect With Clients
Welcome new customers, tell old ones you miss them, send birthday offers. With a reliable POS system, you can set up the email marketing campaign one time and one time only. Going forward, it will be sent out automatically. No More Manual Email Importing
With the integration to a reliable POS system, you only have one set of customer data. Any customer added at the point of sale is also added to your email address list in the system automatically. Sales Returns
You can not only view who is clicking on or opening your emails, but also see the sales being driven by your campaigns. Thanks to robust campaign reporting, the true ROI of your emails becomes evident at a glance.
CASI Pharmaceuticals : Announces Launch of EVOMELAÂ® (melphalan for injection) in China
ROCKVILLE, Md. – CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China , U.S. , and throughout the world, announces the product launch of EVOMELA® (melphalan for injection) in China which is the first commercial product for the Company.
EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China .
, Ph.D., CASI’s Chairman and Chief Executive Officer commented, “This is a proud milestone for CASI. We have an established commercial and supply chain infrastructure with hospitals and physicians ready to accommodate the anticipated demand for this vital treatment. The launch of EVOMELA® officially marks the transition of CASI to a full-scale commercial operation. We look forward to advancing our product line and commercializing additional products from our hematology oncology portfolio, as well as other products where high unmet medical needs exist.” EVOMELA®, now owned by Acrotech Biopharma LLC ., is one of three drugs that were part of a licensing agreement with Spectrum Pharmaceuticals, Inc. which also includes ZEVALIN® and MARQIBO®.
About Multiple Myeloma
Multiple myeloma is a malignant hematological disorder that is characterized by abnormal proliferation of clonal plasma cells in the bone marrow and the secretion of monoclonal immunoglobulins that are detectable in the serum or urine. Multiple myeloma accounts for 10-13% of hematological malignancies1,2 and in Western countries, the estimated incidence is 5.6 cases per 100,000 persons2. The estimated incidence of multiple myeloma in China is ~2.0 cases per 100,000 persons3, for an estimated annual incidence of approximately 27,8003. The estimated number of patients in China with multiple myeloma who are candidates for auto-hematopoietic stem cell transplantation is estimated to be approximately 16,900 cases per year. The current number of patients with multiple myeloma who undergo auto-hematopoietic stem cell transplantation in China is estimated to be approximately 800 cases per year. Autologous stem cell transplantation (ASCT) has been demonstrated to improve complete response rates and prolong median overall survival in patients with multiple myeloma1,3 and is considered standard of care for transplant-eligible patients. The preferred conditioning regimen for ASCT is high dose melphalan 200mg/m2, it is the golden standard conditioning treatment.
1. S. Rajkumar
, Mayo Clin Proc
. 2016 January; 91(1): 101-119 2. A. Palumbo, N Engl J Med, 2011; 364: 1046-60
3. J. Lu
, Blood Cancer Journal (2014) 4, e239; doi:10.1038/bcj.2014.55 About CASI Pharmaceuticals
CASI Pharmaceuticals is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China , the U.S. , and throughout the world. CASI’s product pipeline features (i) an autologous anti-CD19 T-cell therapy investigative product (CNCT19) being developed for the treatment of B-ALL and NHL; (ii) CID-103, an anti-CD38 monoclonal antibody being developed for the treatment of hematological malignancies; (iii) three U.S. Food and Drug Administration (FDA)-approved hematology oncology drugs in-licensed from Acrotech Biopharma L.L.C. and its affiliates for which CASI has exclusive rights to the greater China market, consisting of EVOMELA® (Melphalan for Injection), ZEVALIN® (Ibritumomab Tiuxetan) and MARQIBO® (Vincristine Sulfate Liposome Injection); and (iv) a portfolio of FDA-approved and pending abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate (TDF) indicated for the treatment of hepatitis B virus. CASI has offices in Rockville, Maryland and a wholly owned subsidiary in Beijing, China through which our China operations are conducted. More information on CASI is available at www.casipharmaceuticals.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including: the difficulty of executing our business strategy in China ; our lack of experience in manufacturing products and uncertainty about our resources and capabilities to do so on a clinical or commercial scale; risks relating to the commercialization, if any, of our products and proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks); our inability to predict when or if our product candidates will be approved for marketing by the FDA, NMPA, or other regulatory authorities; our inability to enter into strategic partnerships for the development, commercialization, manufacturing and distribution of our proposed product candidates or future candidates; the volatility in the market price of our common stock; risks relating to the need for additional capital and the uncertainty of securing additional funding on favorable terms; risks associated with CID-103, CNCT19, and our product candidates; risks associated with CID-103, CNCT19, and our other early-stage products under development; risks that results in preclinical and early clinical models are not necessarily indicative of later clinical results; uncertainties relating to preclinical and clinical trials, including delays to the commencement of such trials; the lack of success in the clinical development of any of our products; and our dependence on third parties. Such factors, among others, could have a material adverse effect upon our business, results of operations and financial condition. We caution readers not to place undue reliance on any forward-looking statements, which only speak as of the date made. Additional information about the factors and risks that could affect our business, financial condition and results of operations, are contained in our filings with the U.S. Securities and Exchange Commission , which are available at www.sec.gov.
EVOMELA®, Zevalin® and Marqibo® are proprietary to Acrotech Biopharma LLC and its affiliates. COMPANY CONTACT: CASI Pharmaceuticals, Inc. 240.864.2643 [email protected] INVESTOR CONTACT: Solebury Trout Jennifer Porcelli
646.378.2962 [email protected] .
(C) 2019 M2 COMMUNICATIONS, source M2 PressWIRE